Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jul;66(1):177–180. doi: 10.1038/bjc.1992.238

89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.

S D Fosså 1, E Paus 1, M Lochoff 1, S M Backe 1, M Aas 1
PMCID: PMC1977884  PMID: 1379058

Abstract

Hematological and biochemical parameters were evaluated in 31 patients receiving 150 MBq 89Strontium (89Sr) intravenously due to painful skeletal metastases from hormone resistant prostate cancer. Two and 3 months after the injection prostate specific antigen (PSA) had increased by a median of 36% and 100%, respectively, as compared to the pretreatment value whereas alkaline phosphatase (APHOS) had decreased by about 20% (median). The leucocyte and platelet counts were reduced by about 20-35%, without reaching grade greater than or equal to 2 toxicity. Pain relief was reported in 14 of 29 evaluable patients at 2 months and in 11 of 23 patients at 3 months. It is concluded that 89Sr represents a worthwhile therapeutic modality in the palliation treatment of patients with hormone resistant prostate cancer, though the biological significance of frequently increasing PSA and decreasing APHOS is not yet completely understood.

Full text

PDF
177

Images in this article

179Figure 2
on p.179

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dorrepaal K. L., Aaronson N. K., van Dam F. S. Pain experience and pain management among hospitalized cancer patients. A clinical study. Cancer. 1989 Feb 1;63(3):593–598. doi: 10.1002/1097-0142(19890201)63:3<593::aid-cncr2820630332>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  2. Fosså S. D., Hosbach G., Paus E. Flutamide in hormone-resistant prostatic cancer. J Urol. 1990 Dec;144(6):1411–1414. doi: 10.1016/s0022-5347(17)39756-2. [DOI] [PubMed] [Google Scholar]
  3. Laing A. H., Ackery D. M., Bayly R. J., Buchanan R. B., Lewington V. J., McEwan A. J., Macleod P. M., Zivanovic M. A. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991 Sep;64(765):816–822. doi: 10.1259/0007-1285-64-765-816. [DOI] [PubMed] [Google Scholar]
  4. Lewington V. J., McEwan A. J., Ackery D. M., Bayly R. J., Keeling D. H., Macleod P. M., Porter A. T., Zivanovic M. A. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954–958. doi: 10.1016/0277-5379(91)90257-e. [DOI] [PubMed] [Google Scholar]
  5. Mackintosh J., Simes J., Raghavan D., Pearson B. Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare". Br J Urol. 1990 Jul;66(1):88–93. doi: 10.1111/j.1464-410x.1990.tb14871.x. [DOI] [PubMed] [Google Scholar]
  6. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  7. Robinson R. G., Blake G. M., Preston D. F., McEwan A. J., Spicer J. A., Martin N. L., Wegst A. V., Ackery D. M. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics. 1989 Mar;9(2):271–281. doi: 10.1148/radiographics.9.2.2467331. [DOI] [PubMed] [Google Scholar]
  8. Scher H. I., Curley T., Geller N., Engstrom C., Dershaw D. D., Lin S. Y., Fitzpatrick K., Nisselbaum J., Schwartz M., Bezirdjian L. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol. 1990 Nov;8(11):1830–1838. doi: 10.1200/JCO.1990.8.11.1830. [DOI] [PubMed] [Google Scholar]
  9. Soloway M. S., Hardeman S. W., Hickey D., Raymond J., Todd B., Soloway S., Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195–202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  10. Tannock I., Gospodarowicz M., Meakin W., Panzarella T., Stewart L., Rider W. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989 May;7(5):590–597. doi: 10.1200/JCO.1989.7.5.590. [DOI] [PubMed] [Google Scholar]
  11. Zelefsky M. J., Scher H. I., Forman J. D., Linares L. A., Curley T., Fuks Z. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens. Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1281–1285. doi: 10.1016/0360-3016(89)90537-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES